Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion (EILO)

November 4, 2026 updated by: Rita R. Patel, Indiana University

The overall objectives of the proposed research are to:

  1. Evaluate the diagnostic validity of a novel mechano-acoustic signatures of task-characteristic activity during symptomatic and asymptomatic breathing in Exercise-Induced Laryngeal Obstruction (EILO) patients with the use of a novel miniature, soft wearable skin-mounted device,
  2. Identify the mechanism/s of paradoxical respiratory control in EILO by quantifying the relationship between pulmonary mechanics, partial pressure of carbon dioxide (PCO2) maintenance, and vocal fold aperture prior to and during symptomatic and asymptomatic exercise ventilation, and
  3. Identify unique biophysiological factors contributing to EILO among exercisers with and without EILO. Findings will be highly novel and clinically significant for early identification and management of EILO.

The main study will enroll 60 participants with EILO and 60 without EILO to complete three separate visits:

  1. Exercise treadmill study
  2. Free running with the device on the neck
  3. Undergoing MRI (Magnetic Resonance Imaging) of the vocal tract.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Main Study

At the first study visit, participants will sign informed consent, complete study questionnaires, have their height, weight, and body composition measured, and perform resting pulmonary function tests. Participants will then warm up on the treadmill for 10 minutes. An endoscope will be placed in one nostril until the vocal folds are visible, and subjects will be fitted with a chest strap heart rate monitor, an oro-nasal face mask, and the mechanoacoustic device. This sensor is placed on the neck with a velcro band. Participants will then undergo a graded exercise test during which a carbon-dioxide enriched gas mixture will be administered. The amount of the gas mixture will be titrated based on measures of the participant's breathing and lung function. This visit will be video recorded.

At the second study visit, participants will be asked to again wear the mechanoacoustic device while free running for 10 minutes in a large room or on a track. This visit will be video-recorded.

At the third study visit, participants will be asked to undergo an MRI scan, during which they will perform a variety of breathing exercises including rest breathing, rapid breathing, pursed lip breathing, sniff, and open mouth breathing. Research personnel will instruct participants in the various breathing techniques prior to the scan.

The study visits may occur in any order.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Indiana
      • Bloomington, Indiana, United States, 47401
        • Recruiting
        • Indiana University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 26 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria for Exercise-Induced Laryngeal Obstruction (EILO):

  • Physically active >2.5 hours per week
  • Patients with EILO, as diagnosed by routine clinical examination by physician and/or speech language pathologist
  • Age range of 18-26 years
  • Greater difficulty breathing inside compared to out and difficulty breathing which is exacerbated at peak exercise and stops 1-5 minutes after exercise
  • Score of 7 or higher on the Dyspnea Index, which is a validated instrument to capture participant self-report of upper airway dyspnea symptoms.
  • Classified as low risk, based on the modified Physical Activity Readiness Questionnaire (PAR-Q) questionnaire, body mass index, and non-smoking status
  • Negative history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers.
  • No metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc.

Inclusion Criteria for Controls

  • Physically active >2.5 hours per week
  • Age range of 18-26 years
  • Classified as low risk, based on the modified PAR-Q questionnaire, body mass index, and non-smoking status
  • Negative history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers.
  • No metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc.

Exclusion Criteria for EILO:

  • Individuals older than 26 years and younger than 18 years of age.
  • Women who are pregnant or could possibly be pregnant.
  • A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire
  • Current smoker
  • Positive history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers.
  • Presence of metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc.
  • Do not report the following: Greater difficulty breathing inside compared to out and difficulty breathing which is exacerbated at peak exercise and stops 1-5 minutes after exercise

Exclusion Criteria for Controls

  • Individuals older than 26 years and younger than 18 years of age.
  • Women who are pregnant or could possibly be pregnant.
  • A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire
  • Current smoker
  • Positive history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers.
  • Presence of metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc.
  • Significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: EILO Participants

Breathing Hypercapnic Gas (10% CO2 (carbon dioxide) and 21%O2 (oxygen), balance N210% (nitrogen))

A custom developed mechanoacoustic sensor will be worn on the neck using a Velcro strap. The device will collect audio recordings of breathing and breath sounds and will collect muscle activity from the neck muscles.

Active Comparator: Control Participants

Participants without Exercise-induced laryngeal obstruction (EILO).

Breathing Hypercapnic Gas (10% CO2 (carbon dioxide) and 21%O2 (oxygen), balance N210% (nitrogen))

A custom developed mechanoacoustic sensor will be worn on the neck using a Velcro strap. The device will collect audio recordings of breathing and breath sounds and will collect muscle activity from the neck muscles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Device measurements from real time running
Time Frame: Baseline and Periprocedural

Muscle activation of cricothyroid/sternohyoid muscle measured via customized surface electromyography amplifier

Baseline and Periprocedural
Device measurements from real time running
Time Frame: Baseline and Periprocedural

Normalized amplitude (100% of maximum voluntary contraction) Burst duration (milliseconds) prior to and during Exercise-Induced Laryngeal Obstruction event of laryngeal closure.

Baseline and Periprocedural
Device measurements from real time running
Time Frame: Baseline and Perioprocedural

Exercise-Induced Laryngeal Obstruction signature detected via ultra-low noise micro-electromechanical (MEMS) microphone amplitude (dB) prior to and during EILO. EILO signature detected via accelerometer (g, where g represents the gravitational acceleration of 9.8 m/s2) prior to and during EILO

Baseline and Perioprocedural
Treadmill testing
Time Frame: Baseline and Perioprocedural

Breathing frequency (breaths per minute)

Baseline and Perioprocedural
Treadmill testing
Time Frame: Baseline

Tidal volume (Liters)

Baseline
Treadmill testing
Time Frame: Breath-by-breath baseline and Perioprocedural

Ventilation (Liters/minute)

Breath-by-breath baseline and Perioprocedural
Treadmill testing
Time Frame: Baseline and Periprocedural

Partial pressure of arterial carbon dioxide estimated from end-tidal partial pressure of carbon dioxide; PetCO2) (mmHg)

Baseline and Periprocedural
MRI Upper Airway Size
Time Frame: Baseline

Length (mm), width (mm), and cross-sectional area (mm2) of oropharynx, supraglottis, glottis, immediate subglottis.

Baseline
Upper Airway Aerodynamics
Time Frame: Baseline and Periprocedural

pressure (Pa) across oropharynx, supraglottis, and subglottis

Baseline and Periprocedural
Upper Airway Aerodynamics
Time Frame: Baseline and Periprocedural

volume flow rate (l/s) across oropharynx, supraglottis, and subglottis

Baseline and Periprocedural
Upper Airway Aerodynamics
Time Frame: Baseline and Periprocedural

flow velocities (m/s) across oropharynx, supraglottis, and subglottis

Baseline and Periprocedural

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-rating of dyspnea
Time Frame: Baseline

Participants will rate breathing intensity and breathing unpleasantness on a Visual Analog Scale of 0 to 100mm, where 0 indicates not at all and 100 indicates maximal imaginable intensity/unpleasantness.

Baseline
Profile of Mood States (POMS)
Time Frame: Baseline

The POMS will be used to evaluate the participants' mood and to better understand how the emotional state relates to physical responses during testing. The POMS measures different aspects of mood on a 5-point Likert scale from 0 (not at all) to 4 (extremely).

Baseline
Menstrual Screening Questionnaire
Time Frame: Baseline

Female participants will complete a screening questionnaire about menstruation history and use of hormonal birth control which will be used to evaluate the relationship between EILO and menstruation.

Baseline
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline

The PSQI will be used to evaluate the relationship between sleep and exercise. Total PSQI scores range from 0 to 21 with lower scores indicating better sleep quality.

Baseline
International Physical Activity Questionnaire (IPAQ)
Time Frame: Baseline

Participants will complete the IPAQ which collects information on the frequency and duration of physical activities.

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Rita Patel, Indiana University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 12, 2026

Primary Completion (Estimated)

January 20, 2032

Study Completion (Estimated)

January 20, 2032

Study Registration Dates

First Submitted

January 13, 2026

First Submitted That Met QC Criteria

February 11, 2026

First Posted (Actual)

February 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 29009
  • R01DC023381 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be available indefinitely, as per NIH's Data Management and Sharing Policy to maximize the appropriate sharing of scientific data.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.